Patent application number | Description | Published |
20120327680 | REFLECTOR SIGNAL LAMP HAVING A HIDDEN LIGHT SOURCE - A signal lamp for a front and rear lighting of a vehicle includes at least one light source for emitting light, wherein the at least one light source is hidden from view; a reflector for reflecting the light emitted by the at least one light source away from the vehicle; and at least one light guide disposed between the reflector and a cover of the signal lamp, the at least one light guide having a first end and a second end, wherein the first end is disposed adjacent the at least one light source and the second end is located adjacent a focus point of the reflector. | 12-27-2012 |
20140233251 | BLOCK LIGHT MODULE - A light module for a motor vehicle is disclosed. The light module includes a light source and a reflecting unit. The light module also includes an optical waveguide, wherein the waveguide is formed by a plate-shaped body having an L-shaped cross section, the light-reflecting unit comprises a reflector arranged in front of a shorter input part of the waveguide, and wherein at a place where a shorter inlet part of the waveguide passes into a longer outlet part of the waveguide, an angled surface is provided for total reflection of light passing through the shorter inlet part of the waveguide to the longer outlet part of the waveguide, wherewith a bottom area and an adjacent face of the outlet part of the waveguide are provided with a white coating. | 08-21-2014 |
20140334171 | LIGHTING DEVICE - Lighting device, which is intended especially for external end lighting of motor vehicles, consists of an elongated light guide, provided with a light source at least at one of its ends and located in the space between the white rear cover of the lighting device and its front lens, while along the light guide on the side facing the front lens there is produced a transparent shielding filter in the form of a strip, for shielding the light guide, which is provided with a set of optical elements for directing the guided luminous flux onto the exit surface of the light guide, which is oriented in the direction of the internal surface of the white rear cover. | 11-13-2014 |
Patent application number | Description | Published |
20080293952 | Method for the Preparation of (S)-N-Methyl-3-(1-Naphthyloxy)-3-(2-Thienyl)Propylamine Hydrochloride (Duloxetine) - A method of preparation of (S)—N-methyl-3-(1-naphthyloxy)-3-(2-mienyl)propylamine of Formula (I) and its pharmaceutically acceptable salts, comprising a) reaction of (RS)—N,N-dimethyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine with optically active D-tartaric acid or an acid salt derived from D-tartaric acid forming a mixture of diastereoisomeric salts of N,N-dimethyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine and D-tartaric acid (2:1), b) isolation of the salt (S)—N,N-dimethyl-3-(naphthyloxy)-3-(2-thienyl)propylamine/D-tartrate (2:1) from the mixture of diastereoisomeric salts in an organic solvent, water or a mixture thereof and release of (S)—N,N-dimethyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine by action of an inorganic or organic base, c) demethylation of (S)—N,N-dimethyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine by action of an alkylchloroformate of formula ClCOOR (R=C | 11-27-2008 |
20100069649 | METHOD OF PURIFICATION OF (S)-N-METHYL-3-(1-NAPHTYLOXY)-3-(2-THIENYL) PROPYLAMINE HYDROCHLORIDE (DULOXETINE) - A method of purification of (5)-7V-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride of formula I, comprising (a) transformation of the substance of formula I to its free base by the action of an organic or inorganic base in an aqueous environment; and (b) transformation of the base of the substance of formula I to crystalline hydrochloride by the action of hydrochloric acid or gaseous HCl in an organic solvent or a mixture of organic solvents. A method of purification of (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride of formula I, comprising dissolution of this substance in a minimum quantity of methanol containing 0 to 50% of water and its transformation back to the solid phase (precipitation) by addition of a less polar solvent. | 03-18-2010 |
20100105919 | METHOD FOR THE PREPARATION OF ZOLMITRIPTAN - In the preparation of zolmitriptan of formula III the reduction of the diazonium salt to (5)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one of formula IV is performed in a more concentrated mixture and by the effect on an alkali metal disulphite, preferably sodium disulphite. A zolmitriptan toluene solvate, characterized by a toluene content of 9 to 14% by weight according to the gas chromatography determination and by a maximum of the corresponding mass loss at temperatures of about 111° C. in the gravimetric analysis record. A zolmitriptan toluene solvate, showing strong Raman bands at the wave numbers of 1443 and 1354 cm | 04-29-2010 |
20120029212 | METHOD FOR THE PREPARATION OF (S)-N-METHYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL)PROPYLAMINE HYDROCHLORIDE (DULOXETINE) - A method for the preparation of a duloxetine hydrochloride salt from a duloxetine base, comprising the steps of: reacting duloxetine base with concentrated hydrochloric acid in ethylmethylketone; and crystallizing duloxetine hydrochloride salt from said concentrated hydrochloric acid in ethylmethylketone. | 02-02-2012 |
20120041227 | NEW SALTS OF DESVENLAFAXINE AND A METHOD OF THEIR PREPARATION - The invention deals with new salts of the desvenlafaxine base of formula (I) with oxalic acid, the new salts being the hydrogen oxalate of formula (II) in the proportion of desvenlafaxine:oxalic acid of 1:1 and hemioxalate of formula (III) in the proportion of desvenlafaxine:oxalic acid of 2:1. | 02-16-2012 |
20140051887 | PHARMACEUTICALLY ACCEPTABLE COCRYSTALS OF N-[2-(7-METHOXYL-1-NAPHTYL)ETHYL]ACETAMIDE AND METHODS OF THEIR PREPARATION - The present invention relates to novel solid forms of agomelatine (I), specifically novel phaamaceutically acceptable cocrystals thereof, as well as to methods of preparing them. Three pharmaceutically acceptable cocrystals of (I) that have physico-chemical properties acceptable for pharmaceutical development were obtained. | 02-20-2014 |